Busey Bank Increases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Busey Bank grew its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 108.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 106,434 shares of the company's stock after purchasing an additional 55,380 shares during the period. Busey Bank's holdings in Novo Nordisk A/S were worth $9,155,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of NVO. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth approximately $25,000. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at $42,000. Albion Financial Group UT boosted its holdings in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after purchasing an additional 278 shares during the period. Finally, Sound Income Strategies LLC raised its position in Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after purchasing an additional 243 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NVO traded up $1.30 on Thursday, reaching $85.33. The company had a trading volume of 5,757,265 shares, compared to its average volume of 9,639,438. The stock has a 50-day moving average price of $94.32 and a 200-day moving average price of $113.82. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The stock has a market capitalization of $382.91 billion, a PE ratio of 27.61, a P/E/G ratio of 0.90 and a beta of 0.45.

Analysts Set New Price Targets

A number of research firms recently weighed in on NVO. Cantor Fitzgerald restated an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Finally, StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S currently has an average rating of "Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.